Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers

NEXT STORY
French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides
PREV STORY
Generex Biotechnology Announces Interview with President & CEO Joe Moscato
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Codiak BioSciences Reports First Quarter 2021 Financial Results and Operational Progress

author_avatar
NASDAQ Market News

NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology

WALTHAM, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the ...

author_avatar
NASDAQ Market News

Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics

author_avatar
NASDAQ Market News